Benzinga | Jul 28, 2020 08:04AM EDT

Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $100

Chardan Capital analyst Gbola Amusa maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $72.5 to $100.